ArticleChina CDC weekly2025
The First Imported Case of Chikungunya Virus Infection - Anhui Province, China, 2025.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Since China's first imported Chikungunya fever (CHIKF) case in 2008, 16 provinces have reported cases, primarily imported from endemic areas in Southeast Asia, South Asia, and Africa. Most of China, including Anhui Province, is non-endemic; Anhui had no cases prior to August 2025. What is added by this report?: This report documents the first laboratory-confirmed imported case of Chikungunya virus (CHIKV) infection in Anhui Province and presents the complete viral genome sequence. Comprehensive clinical documentation characterizes the patient's symptoms in detail, including fever, arthralgia, and cutaneous manifestations, thereby addressing a critical gap in the regional clinical profile of CHIKV infection. Comparative analysis of real-time fluorescent quantitative polymerase chain reaction (qPCR) and Enzyme-Linked Immunosorbent Assay (ELISA) results demonstrated that nucleic acid testing provides superior sensitivity during the acute phase of infection. What are the implications for public health practice?: This case underscores China's escalating CHIKF risk. Key implications are: 1) Establishing a cross-regional surveillance network is vital for enhanced case and vector detection sensitivity; 2) In non-endemic areas, strengthening public health education on CHIKV risks is essential for imported disease control. Effectively reducing the burden of vector-borne diseases requires strengthened international cooperation, multi-sectoral collaboration, and innovative technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.